The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells

Alejandro Vázquez‐Martín(Catalan Institute for Water Research), Javier A. Menéndez(Catalan Institute for Water Research)

Cell Cycle

January 1, 2009

10.4161/cc.8.1.7499

Cited by 251

Related Papers

Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab

|PLoS ONE|2009|245

Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation

|Frontiers in Endocrinology|2018|122

The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer

|Scientific Reports|2013|119

Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs

|Aging|2012|119

Pharmacological and small interference RNA‐mediated inhibition of breast cancer‐associated fatty acid synthase (oncogenic antigen‐519) synergistically enhances Taxol (paclitaxel)‐induced cytotoxicity

|International Journal of Cancer|2005|109